165 related articles for article (PubMed ID: 22269178)
1. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
[TBL] [Abstract][Full Text] [Related]
2. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
3. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
4. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
6. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Sad LM; Younis SG; Elity MM
Med Oncol; 2014 Jul; 31(7):58. PubMed ID: 24935625
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.
Besse B; Massard C; Haddad V; Andre F; Dunant A; Pirker R; Olaussen KA; Brambilla E; Fouret P; Soria JC
Ann Oncol; 2011 Mar; 22(3):575-581. PubMed ID: 20801905
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
13. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
15. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
[TBL] [Abstract][Full Text] [Related]
16. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
[TBL] [Abstract][Full Text] [Related]
17. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Wallerek S; Sørensen JB
Eur Respir Rev; 2015 Jun; 24(136):340-55. PubMed ID: 26028645
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
